Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 9, 2012
Exton, PA, January 9, 2012 -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into two agreements with Fox Chase Cancer Center ("Fox Chase") in Philadelphia, PA...
-
Jan 3, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, January 3, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that Arena has submitted its response to the Complete Response...
-
Jan 3, 2012
Woodcliff Lake, NJ, January 3, 2012 — Eisai Inc. announced today that the Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding...
-
Dec 26, 2011
Woodcliff Lake, NJ, December 26, 2011 - Eisai Inc. announced today that it resubmitted the New Drug Application (NDA) for the investigational AMPA-type glutamate receptor antagonist perampanel for...
-
Dec 15, 2011
Tokyo, Japan, December 15, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...
-
Dec 2, 2011
Morphotek, a subsidiary of Eisai Inc., has decided to terminate FAR122, a study of its investigational agent farletuzumab (MORAb-003), in platinum-resistant ovarian cancer. This decision was based...
-
Dec 2, 2011Aims to Provide Personalized Medicine by Integrating Next-generation Synthetic Organic Chemistry with Patient-Based Cancer Genetics
Tokyo, Japan, December 2, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that the company's U.S. research subsidiary H3 Biomedicine...
-
Dec 1, 2011
Tokyo, Japan, December 1, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its Canadian pharmaceutical sales subsidiary Eisai Limited...
-
Nov 8, 20112011 C.A.R.E. (Commitment to Alzheimer's. Recognition of Excellence.) Pharmacy Award Acknowledges Excellence in Alzheimer's Disease Education and Patient Care
WOODCLIFF LAKE, NJ, November 8, 2011 - Eisai Inc. and the Alzheimer's Association announce today that Max C. Brown, RPh is the recipient of the 2011 C.A.R.E. Pharmacy Award. Mr. Brown has been...
-
Oct 26, 2011Eisai Joins WIPO Sponsored Global Consortium for Neglected Tropical Disease Research and Development
October 26, 2011, Tokyo, Japan -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, ("Eisai") announced today that it has joined WIPO Re:Search, a new global consortium...
-
Oct 25, 2011Funding made possible through the support of Eisai Inc.
Woodcliff Lake, NJ, October 25, 2011 - The Breast Cancer Research Foundation (BCRF) announced today that it has awarded a research grant to Daniel F. Hayes, MD, Director of the Breast Oncology...
-
Oct 17, 2011
Tokyo, Japan, October 17, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered into a neurological drug discovery research...
-
Sep 26, 2011
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, September [26], 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical...
-
Sep 23, 2011
Lugano, Switzerland and Woodcliff Lake, NJ, USA Sept. 23, 2011 - Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program...
-
Sep 7, 2011Enters Collaborative Development Agreement with SFJ Pharmaceuticals for Anticancer Agent E7080 (lenvatinib)
Tokyo, Japan, September 7, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has entered into a collaborative development agreement with...
-
Sep 2, 2011
Woodcliff Lake, NJ , September 2, 2011 -- Eisai Inc. announced today that the company has decided to discontinue global development of rabeprazole sodium extended-release capsules, 50 mg. On...
-
Aug 30, 2011
Woodcliff Lake, NJ, August 30, 2011 - Results presented today of a Phase III pivotal study for the investigational compound perampanel for partial-onset seizures showed that perampanel, 8 mg and...
-
Aug 16, 2011Eisai Laboratorios, S. de R.L. de C.V. to Introduce Eisai's Medicines to People Living in Mexico
Woodcliff Lake, NJ, August 16, 2011 - Eisai Inc. and its parent company Eisai Co., Ltd. today announce the establishment of a subsidiary company in Mexico, which will be named Eisai Laboratorios,...
-
Aug 9, 2011Report to be Included in Response to Lorcaserin CRL
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, August 9, 2011 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today results from a Pathology Working Group's (PWG) re-adjudication...
-
Aug 2, 2011
SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 2, 2011 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin...
-
Jul 29, 2011
Woodcliff Lake, NJ, July 29, 2011 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Refusal to File letter in response to the company's New Drug...
-
Jul 19, 2011
Tokyo, Japan, July 19, 2011 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") today announced the launch of its novel anticancer agent Halaven in Japan for the...
-
Jul 13, 2011
Woodcliff Lake, NJ, July 13, 2011 - Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking...
-
Mar 30, 2010
Eisai Inc. today announced that it has submitted simultaneous regulatory applications for approval of eribulin mesylate (also known as E7389) for the treatment of locally advanced or metastatic...
-
Mar 25, 2010
Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will...